drugset / Trial / NCT03872453
Acute Treatment Trial in Adult Subjects With Migraines
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of the study is to evaluate the safety and efficacy of three different intranasal dose levels of zavegepant (BHV-3500), relative to placebo, in the acute treatment of moderate to severe migraine.
Timeline
- Start
- 2019-03-25
- Primary completion
- 2019-10-31
- Completion
- 2019-11-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zavegepant | Small molecule | 5 mg | Intranasal |
| Subject | Zavegepant | Small molecule | 10 mg | Intranasal |
| Subject | Zavegepant | Small molecule | 20 mg | Intranasal |